Sodium thiosulphate for the treatment of ectopic calcifications

Patent metadata

Field	Value
Publication number	US-9629872-B2
Application number	US-201314398776-A
Country	US
Kind code	B2
Filing date	May 10, 2013
Priority date	May 10, 2012
Publication date	Apr 25, 2017
Grant date	Apr 25, 2017

Abstract

The present invention relates to pharmaceutical compositions comprising sodium thiosulphate dispersed in a hydrophile-in-lipophile emulsion, and the use thereof for topical administration for the treatment of an ectopic calcification and/or of the consequences thereof in an individual, the sodium thiosulphate being in the form of a pharmaceutical composition comprising, in addition, a hydrophile-in-lipophile emulsion. The invention also relates to a method for preparing these pharmaceutical compositions.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising sodium thiosulfate and a hydrophile-in-lipophile emulsion, wherein the content by weight of sodium thiosulfate is from 5% to 25% relative to the total weight of said composition, and wherein the hydrophile-in-lipophile emulsion comprises a lipophilic component that is solid at room temperature, a lipophilic component that is liquid at room temperature, and a hydrophilic component that is liquid at room temperature, and wherein the lipophilic component that is solid at room temperature is present at a content by weight of 5% to 28% relative to the total weight of said composition.

2. A pharmaceutical composition according to claim 1 , wherein the ratio by weight of the lipophilic component that is liquid at room temperature to that of the hydrophilic component that is liquid at room temperature is from 0.8 to 1.9.

3. A pharmaceutical composition according to claim 1 , wherein the ratio by weight of the lipophilic component that is liquid at room temperature to that of the hydrophilic component that is liquid at room temperature is from 1 to 1.9.

4. A pharmaceutical composition comprising sodium thiosulfate and a hydrophile-in-lipophile emulsion, wherein the content by weight of sodium thiosulfate is from 5% to 25% relative to the total weight of said composition, and wherein the hydrophile-in-lipophile emulsion comprises a lipophilic component that is solid at room temperature, a lipophilic component that is liquid at room temperature, and a hydrophilic component that is liquid at room temperature, wherein the emulsion comprises, by weight relative to the total weight of the emulsion:
a) 7%-30% of a lipophilic component that is solid at room temperature; and
b) 45%-65% of a lipophilic component that is liquid at room temperature; and
c) 15%-40% of a hydrophilic component that is liquid at room temperature.

5. A pharmaceutical composition according to claim 1 , wherein said lipophilic component that is liquid at room temperature comprises at least one vegetable oil.

6. A pharmaceutical composition according to claim 1 , wherein said hydrophilic component that is liquid at room temperature comprises water, and optionally one or more solvents and/or water soluble additives.

7. A pharmaceutical composition according to claim 1 , wherein the content by weight of sodium thiosulfate is from 8% to 12% relative to the total weight of said composition, and wherein the hydrophile-in-lipophile emulsion comprises white beeswax, sweet almond oil, rose water, and sodium borate.

8. A method of treatment of an ectopic calcification and/or of the consequences thereof in an individual, said method comprising administering topically an effective amount of a pharmaceutical composition according to claim 1 to said individual, the sodium thiosulphate being in the form of a pharmaceutical composition comprising, in addition, a hydrophile-in-lipophile emulsion.

9. The method according to claim 8 , the calcification being a cutaneous or subcutaneous calcification.

10. The method according to claim 8 , the calcification being a metastatic calcification, a dystrophic calcification, a iatrogenic calcification, an idiopathic calcification, a calcification associated with calciphylaxis, or a subcutaneous ectopic ossification.

11. The method according to claim 8 , the calcification being associated with a disease or pathological condition selected from the group consisting of primary hyperparathyroidism, vitamin D intoxication, milk drinker's syndrome, hypercalcemia, secondary hyperparathyroidism, renal failure, hyperphosphatemia, scleroderma, dermatomyositis, mixed connective tissue diseases, lupus, CREST syndrome, Elhers-Danlos syndrome, pseudo xanthoma elasticum, Werner's syndrome, late cutaneous porphyria, pseudo hypoparathyroidism, pseudo pseudo-hypoparathyroidism, venous or arterial insufficiency, diabetes, scrotal calcinosis, ossifying myositis, post-traumatic ectopic ossifications and any other disease or pathological condition caused by calcium crystal deposit(s).

12. A method for preparing a composition according to claim 1 , comprising a step of dispersion of the sodium thiosulfate in a hydrophile-in-lipophile emulsion, the sodium thiosulfate having optionally been previously dissolved in a hydrophilic solution.

13. The method according to claim 11 , wherein hyperphosphatemia is genetic hyperphosphatemia.

14. The method according to claim 11 , wherein dermatomyositis is the juvenile form of dermatomyositis.

15. The method according to claim 11 , wherein the venous or arterial insufficiency is primary or secondary.

16. The method according to claim 11 , wherein the calcium crystal deposit(s) are hydroxyapatite or calcium pyrophosphate.

Assignees

• Inst Nat De La Sante Et De La Rech Medicale (Inserm)
• Univ Limoges
• Chu De Limoges
• Univ Paris-Sud 11
• Inserm (Institut Nat De La Sante Et De La Rech Medicale)
• Univ Paris-Sud

Inventors

• Ratsimbazafy Voa
• Jost Jeremy
• Guigonis Vincent
• Caudron Eric

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/14

  for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04) · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K33/04 Primary

  Sulfur, selenium or tellurium; Compounds thereof · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title